Fig. 5.

In vitro therapeutic effect. (a)¹O₂ production ability. The absorption spectra of DPBF mixed with Pre-CAP and Cb-Vp at different time intervals after the cessation of UV light pre-irradiation (10 min). (b) Confocal laser scanning microscope images of 4T1 cancer cells exposed to DCFH-DA after different treatments. (c) Relative viabilities of 4T1 cancer cells after being incubated with Vp (0.06 μg mL⁻¹), Cb-Vp (Vp: 0.06 μg mL⁻¹, Cb: 2 × 10⁷ cell mL⁻¹) and Pre-CAP (400 μg mL⁻¹) + Cb-Vp (Vp: 0.06 μg mL⁻¹, Cb: 2 × 10⁷ cell mL⁻¹), then irradiated with white LED light for various durations (1, 3, 5 min). (d) Relative viabilities of 4T1 cancer cells incubated with Pre-CAP (400 μg mL⁻¹) and Cb-Vp of varied Vp concentrations. L refers to LED re-excitation for 2 min. (e) Confocal laser scanning microscope images of Calcein AM (green, live cells)/PI (red, dead cells) co-stained 4T1 cancer cells after different treatments. (f) Flow cytometry analysis of 4T1 cancer cells after different treatments through Annexin V-FITC/PI staining. (Pre-CAP [400 μg mL⁻¹]; Cb [Cb: 5 × 10⁷ cell mL⁻¹]; Cb-Vp [Cb: 5 × 10⁷ cell mL⁻¹, Vp: 0.3 μg mL⁻¹]; Pre-CAP + L and Pre-CAP + Cb-Vp + L [L refers to LED re-excitation for 2 min]; Cb + L [L refers to LED excitation for 5 min]).